Recon: Novavax, Regeneron get nearly $2B in Operation Warp Speed funding; FDA puts Cellectis CAR-T trial on hold after death

• Moderna spars with US scientists over COVID-19 vaccine trials (Reuters)
• FDA warns of false positives with BD coronavirus diagnostic (MedtechDive) (FDA)
• US coronavirus response still crippled by lack of testing, Dr. Scott Gottlieb says (CNBC)
• Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold (Fierce) (STAT) (Endpoints)
• US Will Pay $1.6 Billion to Novavax for Coronavirus Vaccine (NYTimes) (STAT)
• Regeneron bags $450M deal with U.S. government for coronavirus antibody cocktail supply (Fierce) (Endpoints) (Reuters)
• J&J sews up 5 years of coronavirus vaccine supply in $480M-plus deal with Emergent (Fierce)
• Lobbyists tied to Trump represent more than a dozen companies working on Covid-19 (STAT)

• GSK’s anti-HIV drug better at preventing infection, trial finds (Financial Times)
• GlaxoSmithKline pens COVID-19 vaccine pact with Medicago (Fierce) (Press)
• Novartis banks EC approval for Enerzair Breezhaler (PharmaTimes) (Press)
• Johnson & Johnson lowers the price of its TB drug in many poor countries, but is it enough? (STAT)
• CureVac scores $85M loan to scale COVID-19 shot manufacturing at German site (Fierce)

• Fauci on a COVID-19 vaccine: 'We will at least have an answer' in the winter whether it works (NBC)
• Dr. Fauci says coronavirus immunity may be ‘finite,’ duration remains uncertain (CNBC)
• US FDA’s Career Leaders Quietly Emerge As Effective Operators In COVID-19 Response (Pink Sheet)
• A New Generation of Fast Coronavirus Tests Is Coming (NYTimes)
• Coronavirus (COVID-19) Update: Daily Roundup July 6, 2020 (FDA)

• A Shot to Protect Against HIV (NYTimes)
• Patient Is Reported Free of HIV, but Scientists Urge Caution (NYTimes)
• ‘It will consume your life’: 4 families take on rare diseases (NYTimes)
• EMA fast-tracks review of AZ/Daiichi Sankyo’s HER2 drug (PMLive)
• Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease (Fierce)
• Jonathan Sackler, joint owner of opioid maker Purdue Pharma, dies aged 65 (The Guardian)
• Startup PBM Capital Rx, Walmart partner to shed light on specialty, mail-order drug prices (Fierce)
• Proposed changes to lung cancer screening guidance could increase scans among Black patients, women (STAT)
• Second PhIII study for Idorsia's sleep drug returns positive results, but also raises new questions (Endpoints)
• Scientist Makes A Discovery That May Lead To New Drugs For Rare Brain Diseases (NPR)
• India coronavirus: Life-saving Covid-19 drugs sold on Delhi black market (BBC)
• Indian pharma compliance standards improving, regulatory risks here to stay: Ind-Ra (Economic Times)
• AlloVir tests how much an antiviral biotech can reap in a pandemic stock market (Endpoints)
• Boehringer Ingelheim ties the knot with Numab on new antibodies; Cabaletta inks pact with Artisan (Endpoints)
• Flagship execs take a lesson from nature to master ‘gene writing,’ launching a star-studded biotech with big ambitions to cure disease (Endpoints)
• Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale (Endpoints)
• Investors give ailing Unum a lease on life and a whole new suite of experimental cancer drugs (Endpoints)
• RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M Series B (Endpoints)
• EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer (Press)

• 'If the public knew:' Ripple20 shows medical device software cyber weakness (MedtechDive)
• FDA approves Abbott's Bluetooth-connected pacemaker, defibrillator implants (Fierce)
• Propeller's digital inhaler tech to be co-prescribed with Novartis' new asthma med (Fierce)
• Industry Publishes Key Proposals For Development Of Companion Diagnostic Guidance (MedtechInsight)
• Dascena wins FDA beakthrough device designation for AI to predict kidney injury (MassDevice)

• Generics' Bid To Limit IP Loss 'Makes No Sense,' Judge Says (Law360)
• Pharmacies Can't Slip Opioid Nuisance Claims, Counties Say (Law360)
• How Therapeutic Formulations Affect Medical Device Patents (Law360)
• Fed. Circ. Clears Amgen's Avastin Biosimilar In Notice Fight (Law360)
• Sanofi Urges High Court To Expand Arthrex To All (Law360)
• Immunex Corp. v. Sandoz Inc. (Fed. Cir. 2020) (Patent Docs)